
Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.
Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the CABOSUN study in renal cell carcinoma (RCC).
Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the CABOSUN study in renal cell carcinoma (RCC).
The CABOSUN study randomized more than 150 patients between sunitinib (Sutent) and cabozantinib (Cabometyx). These individuals had intermediate- and poor-risk features. The progression-free survival (PFS) for cabozantinib was clearly superior to that of sunitinib, states Jonasch.
According to Jonasch, a number of individuals who were on sunitinib came off very early in the study, which may have skewed the curves somewhat in favor of cabozantinib.


